KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查

Randomized, Controlled Study to Evaluate the Safety and Efficacy of Oxygen-Enriched Epithelium-On Corneal Cross-Linking for the Treatment of Keratoconus.

Kenneth A Beckman, Gregory D Parkhurst, James H Lee, Zaina N Al-Mohtaseb, Michael D Greenwood, Marco Armijo, Valerie Smith, Erin H Leone, Angela C Kothe, Tomas Navratil

Ophthalmol Ther 15(4) 1463-1484

PMID41824263
PMCIDPMC13046903
DOI10.1007/s40123-026-01364-7
发表日期2026-03-13
摘要

摘要

INTRODUCTION: This phase 3, multicenter, sham procedure/placebo-controlled, double-masked, randomized clinical trial evaluated the safety and efficacy of oxygen-enriched epithelium-on corneal collagen cross-linking (CXL) for the treatment of keratoconus. METHODS: The trial enrolled patients aged 13 to 51 years diagnosed with keratoconus. Eyes were randomized in a 2:1 ratio to CXL treatment or sham/placebo. The CXL treatment group (200 eyes) received cross-linking using riboflavin 5'-phosphate ophthalmic solutions 0.239% and 0.177% with ultraviolet A (UV-A) irradiation and supplemental oxygen while the sham/placebo group (112 eyes) received placebo solutions and a sham irradiation procedure. The primary efficacy endpoint was the between-group difference in least squares (LS) mean change from baseline in maximum corneal curvature (Kmax) at month 12. Safety outcomes included adverse events and ophthalmic assessments. RESULTS: At month 12, the LS mean Kmax in the CXL treatment group improved as a change from baseline by 0.5 D (95% confidence interval [CI] 0.7, 0.3; p < 0.0001) and the LS mean Kmax in the untreated sham/placebo group deteriorated by 0.4 D (95% CI 0.1, 0.8: p = 0.0045). The difference between groups was - 1.0 D (95% CI - 1.3, - 0.6; p < 0.0001). Therefore, the study met the primary efficacy endpoint criterion with both a statistically significant and clinically meaningful change in the mean Kmax. There were no serious ocular adverse events nor severe treatment-related adverse events in the study eye. The most common adverse event was punctate keratitis (6.5% vs. 1.8% in the CXL and sham/placebo groups, respectively). CONCLUSION: Epithelium-on CXL using riboflavin ophthalmic solutions (riboflavin 5'-phosphate ophthalmic solutions 0.239% and 0.177%) with UV-A irradiation and supplemental oxygen is safe and effective for the treatment of keratoconus in pediatric patients and adults. TRIAL REGISTRATION: ClinicalTrials.gov identifier NCT05759559.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。